Not Yet RecruitingPhase 2

Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma

35 participantsStarted 2025-08

Plain-language summary

Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed first diagnosis of cHL * Advanced-stage disease: stage IIB with large mediastinal mass and/or extranodal lesions or stage III or IV * No previous treatment for HL with the exception of steroid prephase * Confirmed HIV infection with CD4 counts ≥ 150/μL at registration or \> 250/μL at any time within 8 months prior to HL diagnosis * Continuation of antiretroviral treatment (ART) / Initiation of ART in patients who are ART-naive * Age: 18-60 years Exclusion Criteria: * Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment * Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma * Multi-drug resistant HIV infection or concurrent AIDS-defining conditions * Pregnancy or breastfeeding

What they're measuring

Progression Free Survival

Timeframe: PFS at 1 year

Trial details

NCT IDNCT06919679

SponsorUniversity of Cologne

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-01